Trial was progressed based purely on immunological data and without any patients indicating response to treatment. Follow-on phase II trial found no clinical benefit versus placebo. Likely this is because whilst polyfunctional CD4+ T-cells were observed, few patients displayed antigen-specific CD8+ T-cells. Both signals are likely to be needed for an anti-tumour response. This evidence concerns the gene CD4 and neoplasm.